Jove
Visualize
Contact Us

Related Experiment Videos

Emerging cephalosporins.

Malcolm G P Page1

  • 1Basilea Pharmaceutica AG, PO Box, CH-4005, Basel, Switzerland. Malcolm.page@basilea.com

Expert Opinion on Emerging Drugs
|November 6, 2007
PubMed
Summary
This summary is machine-generated.

New cephalosporins show potent activity against multi-resistant staphylococci, challenging previous beliefs about beta-lactam effectiveness. Ceftobiprole, a leading agent, may offer a new treatment approach for serious infections caused by resistant bacteria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A unified annotation scheme for class D β-lactamases.

Antimicrobial agents and chemotherapy·2025
Same author

Siderophore cephalosporins.

EcoSal Plus·2025
Same author

Revitalizing antibiotic discovery and development through in vitro modelling of in-patient conditions.

Nature microbiology·2024
Same author

Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors.

Nature chemistry·2021
Same author

Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes.

Antimicrobial agents and chemotherapy·2020
Same author

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from <i>Escherichia coli</i>.

Biomolecules·2020
Same journal

σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?

Expert opinion on emerging drugs·2026
Same journal

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same journal

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same journal

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.

Expert opinion on emerging drugs·2026
Same journal

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Expert opinion on emerging drugs·2026
Same journal

Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.

Expert opinion on emerging drugs·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Advanced generation cephalosporins typically target Gram-positive and Gram-negative bacteria.
  • Historically, beta-lactam antibiotics have shown limited efficacy against multi-resistant staphylococci.
  • There is a critical need for novel antibiotics to combat rising antimicrobial resistance.

Purpose of the Study:

  • To evaluate the development of novel cephalosporins with broad-spectrum activity.
  • To investigate the efficacy of these agents against multi-resistant staphylococci.
  • To challenge the established understanding of beta-lactam activity against resistant bacteria.

Main Methods:

  • Clinical development of novel cephalosporin agents.
  • In vitro and in vivo testing against a panel of resistant bacterial strains, including staphylococci.

Related Experiment Videos

  • Comparative analysis of efficacy against standard-generation cephalosporins.

    • Main Results:

    • Several cephalosporins demonstrate potent activity against multi-resistant staphylococci.
    • These agents exhibit broad-spectrum efficacy, including against Gram-positive and Gram-negative bacteria.
    • Ceftobiprole, a leading investigational agent, shows promising results.

    Conclusions:

    • Novel cephalosporins offer a new class of antibiotics with significant potential.
    • These agents challenge the dogma regarding beta-lactam activity against resistant staphylococci.
    • Ceftobiprole's potential approval signifies a new era in treating infections caused by multi-resistant organisms.